Introduction
============

Circulating tumor cells (CTCs) can be identified in the peripheral blood of patients with solid tumors even in early disease stages and their detection and characterization have the potential to lead towards personalized treatment strategies in breast and other cancers \[[@B1]-[@B3]\].

Several technologies exist for CTC detection, but CellSearch® (Veridex, Raritan, NJ, USA) is the only one that has received Food and Drug Administration (FDA) clearance to be used as an aid in monitoring patients with metastatic breast, colorectal and prostate cancer. Compared to other CTC assays \[[@B4]\], CellSearch® is so far the only semi-automated system and has contributed considerably to the development of standards for CTC enumeration. In breast cancer, a multicenter study has shown that ≥5 CTCs/7.5 ml of blood were detected in 49% of 177 patients before starting a new treatment for metastatic disease and their detection was independently associated with worse progression-free and overall survival (PFS and OS) \[[@B5]\]. Subsequently, other studies have confirmed these results \[[@B6]-[@B8]\]. The value of CTC detection by CellSearch® in non-metastatic breast cancer has recently been emerging. Indeed, detection of ≥1 CTC/7.5 ml was reported in 23% of 115 patients with large operable and locally advanced breast cancer before neoadjuvant chemotherapy and was independently associated with worse outcome \[[@B9]\]. In another study, detection of ≥1 CTC/7.5 ml by CellSearch® at the time of surgery and before the administration of adjuvant chemotherapy in 24% of 302 patients was associated with decreased PFS and OS \[[@B10]\]. In the SUCCESS study, ≥1 CTC/23 ml were detected by CellSearch® in 21.5% of 2,026 patients with early breast cancer before adjuvant chemotherapy and the detection was independently associated with poor outcome \[[@B11]\]. In another study ≥1 CTC/30 ml of blood were detected in 19% of 404 patients with stage-I to -III breast cancer before surgery and their detection was independently associated with shorter distant disease-free survival \[[@B12]\]. Beyond enumeration, CTC characterization holds the promise to serve as a *liquid biopsy* to tailor treatment decisions \[[@B1],[@B2]\]. As an example, as HER2 protein overexpression or gene amplification in the primary tumor is currently required for administering anti-HER2 treatment in breast cancer \[[@B13]\], HER2 status on CTCs has also been investigated in breast cancer using CellSearch® and other technologies \[[@B14]-[@B18]\].

More than 400 studies have included CTCs as a biomarker \[[@B19]\]. These include interventional studies assessing the value of CTCs as a treatment decision tool in the metastatic and non-metastatic setting \[[@B20],[@B21]\]. Two studies have validated the analytical performance of CellSearch® for CTC detection in metastatic breast cancer \[[@B22],[@B23]\]. In the metastatic setting, the main contributor to inter-laboratory variation was variability among the readers in image interpretation \[[@B23],[@B24]\]. In non-metastatic breast cancer (BC) more than half of women with detectable CTCs have only 1 CTC/blood volume processed \[[@B9]-[@B12]\]. Therefore, in this setting, image interpretation is crucial, especially if CTC detection is to be used as a tool to decide on secondary adjuvant treatment strategies in the context of a clinical trial. Moreover, no study has addressed potential problems in image interpretation when HER2 expression on CTCs is investigated using CellSearch®, which is an important prerequisite for interventional studies using CTCs in trials testing HER2-directed therapies.

Therefore, we performed an international study to evaluate the inter-reader agreement in the classification of CellSearch® images as CTC and interpretation of HER2-staining on these images. Moreover, we came up with consensus guidelines for image interpretation in the non-metastatic breast cancer setting that were subsequently endorsed by CTC experts participating in this study.

Methods
=======

Patient and samples
-------------------

CellSearch® images from blood samples used for the detection of CTCs and characterization of CTC HER2 protein expression by CellSearch® from breast cancer patients were retrieved for this study. The blood samples were processed at one of the three different laboratories; the Institut Jules Bordet, Belgium (IJB), the Institut Curie, France (IC), and the University of Hamburg, Germany (UH), respectively. The IJB dataset included CellSearch® images from women with non-metastatic (M0) and metastatic (M1) breast cancer treated according to the standard of care in Belgium \[[@B17]\]. The IC dataset consisted of CellSearch® images from women with inflammatory M0 breast cancer participating in the BEVERLY-I and -II phase-2 trials \[[@B25],[@B26]\]. The UH dataset included CellSearch® images from women receiving neoadjuvant chemotherapy in the GeparQuattro and GeparQuinto studies (M0 cohort) \[[@B16],[@B27]\] and women from the Detect Study (M1 cohort) \[[@B18]\]. From each patient sample, a subset of CellSearch® images (images of either CTCs or white blood cells or artifacts) and not the full set of CellSearch® images were provided by investigators from the three independent, academic labs to the principal investigator at IJB who was responsible for the central coordination of the study. Due to technology limitations, at the time the study was initiated, it was not possible to send the full set of CellSearch® images from each patient sample. All CellSearch® images used in the present study are from previously reported studies of CTC detection in breast cancer \[[@B16]-[@B18],[@B25]-[@B27]\]. All women participating in these studies provided informed consent and each study was approved by the respective institutions\' ethical committees. The present study was approved by the IJB ethical committee (CE 2035). Informed consent for the present study was waived by the IJB ethical committee.

Readers
-------

The IJB lab sent the blinded CellSearch® images by email to twenty-two readers from one US and fourteen European academic laboratories as well as to eight readers from two Veridex laboratories. Each CellSearch® image was evaluated independently of the other images. All readers had already received the appropriate training provided by Veridex for the CellSearch® system, which includes training in image interpretation.

Definition of CTC and HER2-positive CTC
---------------------------------------

In CellSearch®, a CTC is defined as an epithelial cell adhesion molecule (EpCAM)-positive cell (round to oval and sometimes polygonal or elongated in shape and at least 4 μm in size) that has positive immunofluoresence staining for a Cytokeratin (CK) (clone C11 and A53-B/A2) epithelial marker and positive staining for the nuclear dye 4\',6-diamidino-2-phenylindole (DAPI) (the nuclear area should be smaller than the cytoplasmic area and at least 50% of the nucleus should be co-located with the cytoplasm). The CTC must also be negative for the leukocyte marker CD45. For this study, the readers were asked to score CTCs with HER2 immunofluoresence staining intensity of 2+, 3+ as HER2-positive and were provided with reference CellSearch® images from breast cancer cell lines (MCF7, BT20, T47D, MDA-MB-453, SKBR3, BT474) with different levels of HER2 expression according to Riethdorf *et al*. \[[@B16]\]. The readers scored each image as follows: No CTC, CTC/HER2-negative (CTC HER2-), or CTC/HER2-positive (CTC HER2+).

Statistics
----------

Results from the eight Veridex readers were summarized to a Veridex consensus (VC) in order to compare each academic reader using percentage (%) agreement and kappa (κ) statistics. We followed the Koch and Landis classification to interpret obtained κ values: concordance was considered bad if κ was less than 0.20, poor if κ was 0.20 to 0.40, moderate if κ was 0.40 to 0.60, good if κ was 0.60 to 0.80, and almost perfect if κ was above 0.81 \[[@B28]\]. VC was reached when there was \>60% agreement between Veridex readers as to whether or not an image was a CTC. When there was \<60% agreement by the Veridex readers for an image, this image was not included in any of the subsequent comparisons. If the VC was that the image was a CTC, then there had to be \>60% agreement on the CTC being either HER2- or HER2+. If there was \<60% agreement about the HER2 positivity or negativity among the Veridex readers for a CTC, this image was not included in any of the subsequent comparisons.

For each of the 22 academic readers, percentage (%) agreement with VC was calculated for the CTC detection question (no CTC versus CTC) and for the question of HER2 expression on CTCs (CTC HER2- versus CTC HER2+). In order to understand problems related to CellSearch® image interpretation, we compared the locations in the distributions of the agreement (%) between VC and the academic readers according to the dataset (IJB versus IC versus UH), disease stage (M0 versus M1), number of detected CTCs in the entire sample (≥5 CTCs versus \<5 CTCs) and administration of systemic treatment before blood sampling (yes versus no) using non-parametric tests (Wilcoxon signed rank and Freedman test). Moreover, within M0 patient samples, we interrogated whether there was different agreement according to the number of CTCs detected in the entire sample (≥3 CTCs versus \<3 CTCs) using the Wilcoxon signed rank test. Finally, we studied CellSearch® images with \<70% agreement between VC and academic readers in order to understand reasons for discordance between readers.

Results
=======

CellSearch® images and patient characteristics
----------------------------------------------

A total of 272 CellSearch® images from 131 patients were analyzed. Table [1](#T1){ref-type="table"} provides information on relevant study demographics. The majority of CellSearch® images analyzed were from patients with M0 breast cancer, with \<5 CTCs in their blood sample and from patients for whom blood sampling for CTC detection was performed before the administration of systemic treatment (Table [1](#T1){ref-type="table"}).

###### 

CellSearch® images and patient characteristics

                                                                **Patients, number (%)**   **CellSearch® images, number (%)**
  ------------------------------------------------------------ -------------------------- ------------------------------------
  **Dataset**                                                                                               
    Institute Jules Bordet                                              34 (26)                         60 (22)
    Institute Curie                                                     60 (46)                         114 (42)
    University of Hamburg                                               37 (28)                         98 (36)
  **Age, years**                                                                                            
    ≤50                                                                 58 (44)                         108 (40)
    \>50                                                                66 (51)                         147 (54)
    Unknown                                                              7 (5)                           17 (6)
  **ER**                                                                                                    
    Negative                                                            54 (41)                         106 (39)
    Positive                                                            68 (52)                         139 (51)
    Unknown                                                              9 (7)                          27 (10)
  **HER2**                                                                                                  
    Negative                                                            103 (79)                        193 (71)
    Positive                                                            15 (11)                         44 (16)
    Unknown                                                             13 (10)                         35 (13)
  **Histology grade**                                                                                       
    1                                                                    5 (4)                           6 (2)
    2                                                                   46 (35)                         85 (31)
    3                                                                   69 (53)                         147 (54)
    Unknown                                                              11 (8)                         34 (13)
  **Histology**                                                                                             
    Ductal                                                              99 (76)                         202 (74)
    Lobular                                                              10 (8)                          12 (4)
    Other                                                                7 (5)                           18 (7)
    Unknown                                                             15 (11)                         40 (15)
  **Stage**                                                                                                 
    M0                                                                  109 (83)                        215 (79)
    M1                                                                  22 (17)                         57 (21)
  **CTC count**^**1**^                                                                                      
    \<5 CTCs                                                            90 (69)                         150 (55)
    ≥5 CTCs                                                             40 (30)                         120 (44)
    Unknown                                                              2 (1)                           2 (1)
  **Systemic therapy before blood sample collection**^**2**^                                                
    No                                                                  87 (65)                         168 (62)
    Yes                                                                 31 (24)                         62 (23)
    Unknown                                                             15 (11)                         42 (15)

^1^One patient with two samples (\<5 CTCs and ≥ 5CTCs) was included; ^2^two patients with samples before and after treatment were included. ER, estrogen receptor; CTC, circulating tumor cell; M0, non-metastatic; M1, metastatic.

Veridex consensus (VC)
----------------------

For each image, the results from the eight Veridex readers were summarized to a VC, as explained in the Methods section. For CTC detection, VC was reached for 267 (98%) of 272 images with an average percent agreement for CTC versus no CTC between the eight Veridex readers of 97% (median 100%, range 63% to 100%). Of the 267 images, 157 (59%) were considered CTCs. For interpretation of HER2 staining on the CTC, VC was obtained for 155 (99%) out of 157 CTCs with an average percent agreement for HER2- versus HER2+ between the eight Veridex readers of 98% (median 100%, range 63% to 100%): 71 (46%) of 155 CTCs were considered as HER2 + .

Agreement between academic readers and Veridex consensus for CTC definition
---------------------------------------------------------------------------

For the question of whether an image was a CTC (no CTC versus CTC), the median agreement between the academic readers and VC was 92% (range 69% to 97%), with a median κ statistic of 0.83 (range 0.37 to 0.93) (Table [2](#T2){ref-type="table"}). We then asked whether agreement between the academic readers and VC was different according to the dataset (IJB versus IC versus UH), disease stage (M0 versus M1), CTC counts (\<5 versus ≥5) and administration of systemic treatment before blood sampling (yes versus no). We observed significantly lower agreement between academic readers and VC for CellSearch® images from patients of the IJB dataset compared to the other datasets, from patients with M0 compared to M1 disease, \<5 CTCs compared to ≥5 CTCs, and blood samples drawn after the administration of systemic treatment as compared to samples drawn before systemic treatment (Table [3](#T3){ref-type="table"}, Additional file [1](#S1){ref-type="supplementary-material"}: Table S1 and Additional file [2](#S2){ref-type="supplementary-material"}: Table S2, online). CellSearch® images from samples with \<5 CTCs were present more frequently in M0 (146 of 213 images, 68%) compared to M1 patients (4 of 57 images, 7%) (Pearson chi-square test, *P* \<0.001) and in the IJB dataset, (52 of 60 images, 87%) compared to the UH (22 of 96 images, 22%) and the IC dataset (76 of 114 images, 67%) (*P* \<0.001). When only images from M0 patients samples were analyzed, lower agreement was observed for images from samples with \<3 CTCs (median 87%, range 66% to 95%) compared to those from samples where ≥ 3CTCs were detected (median 95%, range 77% to 99%), (*P* \<0.001).

###### 

Agreement (%) between academic readers and Veridex consensus (VC)

       **No CTC versus CTC**                  **CTC HER2- versus CTC HER2+**                       
  --- ----------------------- ------- ------ -------------------------------- ----- ------- ------ ----------------
   A            267            91.8%   0.83           Almost perfect           155   81.3%   0.63    Substantial
   B            267            91.4%   0.82           Almost perfect           155   81.3%   0.63    Substantial
   C            267            92.5%   0.84           Almost perfect           155   90.3%   0.81   Almost perfect
   D            267            91.8%   0.83           Almost perfect           155   71.6%   0.47      Moderate
   E            266            95.1%   0.90           Almost perfect           154   93.5%   0.87   Almost perfect
   F            267            92.1%   0.84           Almost perfect           155   87.1%   0.75    Substantial
   G            267            91.4%   0.82           Almost perfect           155   91.0%   0.82   Almost perfect
   H            267            91.4%   0.82           Almost perfect           155   88.4%   0.78    Substantial
   I            267            92.1%   0.84           Almost perfect           155   91.6%   0.84   Almost perfect
   J            267            83.9%   0.65            Substantial             155   76.8%   0.55      Moderate
   K            220            87.3%   0.74            Substantial             117   79.5%   0.59      Moderate
   L            266            92.9%   0.85           Almost perfect           154   94.8%   0.90   Almost perfect
   M            220            87.3%   0.74            Substantial             117   90.6%   0.82   Almost perfect
   N            267            95.9%   0.92           Almost perfect           155   92.3%   0.85   Almost perfect
   O            267            96.6%   0.93           Almost perfect           155   92.9%   0.86   Almost perfect
   P            267            94.4%   0.88           Almost perfect           155   85.2%   0.72    Substantial
   Q            218            91.7%   0.83           Almost perfect           113   84.1%   0.69    Substantial
   R            218            91.7%   0.83           Almost perfect           113   85.8%   0.73    Substantial
   S            220            92.7%   0.85           Almost perfect           117   86.3%   0.73    Substantial
   T            266            69.2%   0.37                Fair                154   51.3%   0.25        Fair
   U            267            91.4%   0.82           Almost perfect           155   91.0%   0.82   Almost perfect
   V            220            91.8%   0.84           Almost perfect           117   82.1%   0.66    Substantial

CTC, circulating tumor cell; RDs, readers; N, number of images. Kappa Agreement, below 0.00 Poor; 0.00 to 0.20 Slight; 0.21 to 0.40 Fair; 0.41 to 0.60 Moderate; 0.61 to 0.80 Substantial; 0.81 to 1.00 Almost Perfect.

###### 

Percent agreement between academic readers and Veridex consensus (VC) overall and according to dataset, disease stage, circulating tumor cell (CTC) count and administration of systemic therapy before blood sample collection

                                                         **Agreement, %**              
  ----------------------------------------------------- ------------------ ----------- ---------
  **All**                                                       92          69 to 97        
  **Dataset**                                                                               
    Institute Jules Bordet                                      81          61 to 97    \<0.001
    Institute Curie                                             97          73 to 99        
    University of Hamburg                                       94          69 to 98        
  **Stage**                                                                                 
    M0                                                          91          70 to 96    \<0.001
    M1                                                          98          64 to 100       
  **CTC count**                                                                             
    \<5 CTCs                                                    88          66 to 95    \<0.001
    ≥5 CTCs                                                     97          74 to 100       
  **Systemic therapy before blood sample collection**                                       
    No                                                          92          74 to 96    \<0.001
    Yes                                                         89          55 to 97        

CTC, circulating tumor cell; M0, Non-metastatic, M1, metastatic.

Agreement between academic readers and Veridex consensus (VC) for HER2 expression on CTCs
-----------------------------------------------------------------------------------------

When only the images that were CTCs according to VC were analyzed for HER2 protein expression (CTC HER2- versus CTC HER2+), the median agreement between the academic readers and VC was 87% (range 51% to 95%), with a median κ statistic of 0.74 (range 0.25 to 0.90) (Table [2](#T2){ref-type="table"}).

Analysis of CellSearch® images with \<70% agreement between academic readers and Veridex consensus (VC)
-------------------------------------------------------------------------------------------------------

There were many images with excellent agreement between academic readers and VC, such as images of intact CTCs (Figure [1](#F1){ref-type="fig"}A). In order to understand the reasons for discordance in image interpretation, we focused on images with \<70% agreement between the academic readers and VC. We identified 25 images with \<70% agreement for the CTC question (CTC versus no CTC) and 14 images with \<70% agreement for the HER2 expression question (HER2- versus HER2+ CTCs). Disagreement was observed for images of CTCs with CK staining that surrounded the nucleus but was either incomplete or granular (Figure [1](#F1){ref-type="fig"}B). A total of 16 of the 25 images with \<70% agreement for the CTC question were considered by some academic readers as CTCs, whereas the VC was that these images were not CTCs. These included images displaying the same morphology in all channels (Figure [1](#F1){ref-type="fig"}C,D) or a nucleus larger than the cytoplasm or \<50% inside the cytoplasm and with cytokeratin (CK) staining not surrounding the nucleus (Figure [1](#F1){ref-type="fig"}E,F). Images with \<70% agreement between academic readers and VC for the HER2 expression question were images from CTCs with intermediate HER2 staining (neither too strong nor absent).

![**Example of an intact circulating tumor cell (CTC) (A), a granular CTC (B) and of images with no CTCs (C,D,E,F) as they display the same morphology in all channels (C,D) or have a nucleus larger than the cytoplasm or not 50% inside the cytoplasm and cytokeratin staining not surrounding the nucleus (E,F).** DAPI, 4\',6-diamidino-2-phenylindole.](bcr3647-1){#F1}

Discussion
==========

To our knowledge, this is the first study to evaluate the inter-reader agreement for CTC detection in both M1 and M0 breast cancer in a large international multicenter study comprising 15 centers from Europe and the United States. Our results show that the inter-reader agreement is high for CTC definition and for characterizing HER2 expression on CTCs.

Lower inter-reader agreement for CTC definition was observed for CellSearch® images of samples from patients with M0 disease, with low CTC counts, samples from the IJB dataset, and samples drawn after the administration of systemic treatment. CellSearch® images of samples with low CTC counts were more frequently observed in the IJB compared to the other datasets and in M0 compared to M1 disease and this can partly explain the lower inter-reader agreement in these groups. In a recently reported study of CTC detection by CellSearch® at the time of surgery in patients with early breast cancer, increasing CTC counts were associated with increasing hazard ratio (HR) for disease progression. The presence of ≥1 CTC, ≥2 CTCs and ≥3 CTCs was associated with a HR of 4.6, 5.5 and 6.7, respectively \[[@B10]\]. Although, this increase in HRs can be attributed to the increase in the number of CTCs, the data from the present analysis imply that this might be also due to the lower false CTC-positive cases in women with increasing CTC counts. Finally, a possible explanation for the lower inter-reader agreement in samples drawn after the administration of systemic treatment is the presence in these samples of granular CTCs that have been demonstrated to be mainly apoptotic, and to be a source of inter-reader disagreement in a previous study \[[@B23]\].

There are some limitations in the way the present validation study was conducted. Although CellSearch® image selection was performed by three independent, academic laboratories, a selection bias towards either CellSearch® images that are easy (typical CTC images) or difficult to interpret (not typical CTC images) cannot be excluded. Moreover, the readers were provided with a subset of CellSearch® images (images of either CTCs or white blood cells or artifacts) and not the full set of CellSearch® images from each patient sample. Therefore, a bias in image selection cannot be excluded. Moreover, the readers were scoring images but were not able to use the Cell Select tool of the CellSearch® system, which allows relocation of a cellular image in the cartridge and study of its characteristics in more detail. As the technology evolves, one can imagine that the exchange of CellSearch® images for central image review will be more easily performed.

The above limitations may partly explain some of the discrepancies observed between readers. Although overall inter-reader agreement was high, agreement was lower in images from M0 patients with \<3 CTCs. In order to improve the performance of academic readers, especially in the setting of non-metastatic breast cancer with low CTC counts, we propose the following: 1) images displaying identical morphology in all channels (CK, DAPI and HER2 if performed) or images with a nucleus larger than the cytoplasm or \<50% inside the cytoplasm should not be considered as CTCs; 2) the authors reporting studies on CTCs using CellSearch® should clearly indicate whether their CTC definition includes only intact CTCs (complete CK staining surrounding the nucleus) or whether it also includes granular CTCs (CK staining that surrounds the nucleus but is either granular or incomplete); 3) in cases of blood samples from M0 patients with low CTC counts (\<3 CTCs) evaluation of images by at least two independent readers - ideally from different labs - should be performed. Such an independent image review is applied in the ongoing European Organization for Research and Treatment of Cancer (EORTC) Treat CTC trial (ClinicalTrials.gov Identifier: NCT01548677). This trial is testing the value of CTC detection to decide for secondary adjuvant treatment in BC.

We propose that investigators conducting studies on CTCs in non-metastatic breast cancer follow these guidelines for CellSearch® image interpretation. The present study might also be a model for similar experiments regarding other image-based CTC technologies. This could facilitate consistent result interpretation across studies on CTC detection and characterization, and accelerate the clinical development of CTC-related biomarkers.

Conclusions
===========

This is the first study to evaluate the inter-reader agreement for CTC detection in both metastatic and non-metastatic BC in a large international multicenter study comprising 15 centers from Europe and the United States. We demonstrated that inter-reader agreement using CellSearch® was high overall but was reduced in non-metastatic breast cancer patients with low CTC counts. This study resulted in consensus guidelines for image interpretation for CTC detection in non-metastatic breast cancer. Continuous training, independent image review and adherence to these consensus guidelines should be considered in studies evaluating the clinical utility of CTC-related biomarkers in non-metastatic breast cancer.
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